ARTICLE | Company News
FDA grants ponatinib Priority Review
October 25, 2012 12:29 AM UTC
FDA accepted and granted Priority Review to an NDA from Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) for ponatinib to treat resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia chro...